Syngene International Ltd

Syngene International Earnings Call Transcript: Key Takeaways

Syngene reports a transitional quarter with sequential recovery but YoY declines due to the absence of the large Librela revenue stream.

Syngene International Investor Presentation: Key Takeaways

Q2 FY27 revenue Rs 833 Cr (down 9% YoY, up 13% QoQ). Operating EBITDA margin 18% on forex hedge losses. PAT before exceptionals Rs 38 Cr (down 44% YoY). Focus on integrated CRDMO and first Bayview biologics deal.

Syngene International Results Update

Syngene reported Q2 FY27 revenue of Rs 833 Crore, up 13% sequentially, with PAT of Rs 32 Crore. Release includes P&L highlights and business updates.

Syngene International Management Change

Syngene reports changes in senior management: two heads move from SMP to Non-SMP, Ajay Tandon resigns effective October 30, 2026, and CFO Deepak Jain plans to leave. The CFO is a KMP, so this is a material leadership change.

Syngene International Q2 FY27 Results: Net Profit ₹32.2 Cr, Down 52.0% YoY

Syngene International Ltd reported revenue from operations of ₹832.7 Cr (-8.6% YoY) and net profit of ₹32.2 Cr (-52.0% YoY) for Q2 FY27.

Key figure

Net profit ₹32.2 Cr · -52.0% YoY

Syngene International Other Announcement

Syngene International Limited has submitted the quarterly certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026.

Syngene International Board Meeting Date

Syngene International Limited will hold a board meeting on October 27, 2026, to approve the standalone and consolidated financial results for the quarter ended September 30, 2026.

Syngene International Management Change

Syngene International Limited announced the resignation of Mr. Pramuch Goel, Head of Corporate Affairs & Communications and Senior Management Personnel, effective September 21, 2026.

Syngene International Other Announcement

Syngene International Limited has issued a communication to shareholders regarding the remittance of the final dividend for the financial year 2025-26.

Syngene International Employee Stock Options

Syngene International has granted 14,26,061 Performance Share Units (PSUs) to eligible employees under the company's 2023 Long Term Incentive Performance Share Plan.

Syngene International Acquisition Worth ₹2.52 Cr

Syngene International Limited is investing ₹2.52 Crore to acquire a 12.44% equity stake in Ampin C&I Power Twelve Private Limited for renewable energy power consumption.

Value

₹2.52 Cr

Syngene International Investor Presentation: Key Takeaways

Syngene reports Q1 FY27 revenue of Rs 736 Cr (-16% YoY). Performance was impacted by low offtake from a major client and forex losses.

Syngene International Annual General Meeting

Syngene International Limited held its 33rd Annual General Meeting on July 29, 2026. The meeting transacted business including the adoption of financial statements and dividend declaration.

Syngene International Management Change

Independent Director Mr. Kush Parmar resigned from Syngene International, effective July 29, 2026, due to overseas commitments. He also vacated his board committee memberships.

Syngene International Results Update

Syngene International Ltd announced its Q1 FY27 financial results, reporting Rs. 736 Cr in revenue from operations and Rs. 91 Cr in operating EBITDA.

Syngene International Q1 FY27 Results: Net Loss of ₹9 Cr

Syngene International Ltd reported revenue from operations of ₹736 Cr (-15.8% YoY) and a net loss of ₹9 Cr for Q1 FY27.

Key figure

Net loss ₹9 Cr

Syngene International Capital Structure Change

Mirae Asset Mutual Fund sold 861,450 shares of Syngene International Ltd via an open market transaction. The sale reduces their holding in the company.

Syngene International Management Change

Syngene International announced that General Counsel Surender Sharma will leave the company on July 15, 2026. He resigns by mutual consent to pursue other career opportunities.

Syngene International Board Meeting Date

Syngene International's board will meet on July 29, 2026, to approve Q1 FY27 financial results. An analyst call is scheduled for July 30, 2026.

Syngene International Other Announcement

B S R & Co. LLP resigned as statutory auditors of Syngene's material subsidiary, SSSL, effective July 7, 2026. The resignation aims to align auditors across the group.

Syngene International Legal & Regulatory

Syngene disclosed a tax litigation update, receiving a Rs.0.86 Cr refund for AY 2014-15. The company expects no material financial impact, reducing contingent liability.

Value

₹0.86 Cr

Syngene International Annual General Meeting

Syngene International will hold its 33rd AGM on July 29, 2026, to approve financials, dividend, and director appointments. The notice includes details on remuneration for new MD & CEO.

Syngene International Management Change

Siddharth Mittal has been appointed as Managing Director and CEO of Syngene International. He succeeds Peter Bains effective July 1, 2026.

Syngene International Employee Stock Options

Syngene International Limited allotted 7,29,727 equity shares worth ₹0.73 Crore to its ESOP Trust. The issuance increases total paid-up capital to 40,36,69,147 shares.

Value

₹0.73 Cr

Syngene International Annual General Meeting

Syngene International Limited issued a postal ballot notice to redesignate Ms. Kiran Mazumdar-Shaw as Executive Chairperson. The five-year tenure commences April 2026.

Execution

2026-04-01 to 2031-03-31

Syngene International Annual General Meeting

Syngene International initiated a postal ballot for appointing Ms. Kiran Mazumdar-Shaw as Executive Chairperson with ₹4 Crore annual remuneration. This leadership transition aims to align with corporate strategy.

Value

₹4.00 Cr

Execution

5 years

Syngene International Legal & Regulatory

Syngene International paid Rs. 0.04 Crore in penalties to BSE and NSE for board committee composition deviations. The company has since reconstituted the committee to ensure compliance.

Value

₹0.04 Cr

Syngene International Merger & Restructuring

Syngene International Limited announced the voluntary liquidation of its wholly owned subsidiary. The closure streamlines the company's corporate structure and has no material financial impact.

Syngene International Merger & Restructuring Worth ₹0.94 Cr

Syngene approved the voluntary liquidation of its non-operational subsidiary, SMSL. The move streamlines corporate structure without impacting consolidated financial performance.

Value

₹0.94 Cr